Loading...
Branded ingredient
MitoSober® PQQ
by Bonerge Lifescience · bonerge.com
Tier 1 · listedGMPHACCPHalalISO 22000
Request sample
Sign in to send a request. Suppliers are told your name, company, role and country.
- Scientific name
- -
- Active
- Pyrroloquinoline Quinone
- Assay
- min. 100 % Chromatographic purity approaches 100
- Physical form
- Oil · Powder · Water-Soluble Form
- Dosage
- 20 mg
- MOQ · lead time
- 1 Kg
About this ingredient
MitoSober® PQQ is one of Bonerge Lifescience's branded ingredients. Built on a proprietary patented crystal form of pyrroloquinoline quinone disodium salt, it has completed the FDA GRAS notification process, among the first PQQ ingredients to do so. Produced using a patented fermentation process, it reaches nearly 100% chromatographic purity by HPLC with no significant impurity peaks, and dissolves readily. PQQ helps promote mitochondrial biogenesis and enhance cellular energy production. MitoSober is Non-GMO, vegan, and gluten-free.
Categories
Cognitive healthAntioxidant & cellular healthInflammation supportHealthy aging
Specification
5 parametersReproduced exactly as the manufacturer states them. A parameter the catalogue does not hold shows as a dash rather than a default.
Identity
| Parameter | Value |
|---|---|
| Active compound | Pyrroloquinoline Quinone |
| Physical form | Oil · Powder · Water-Soluble Form |
Standardization
| Marker | Guaranteed level | Applies to | Test method |
|---|---|---|---|
| Chromatographic purity approaches 100 | min. 100 % | - | - |
Use and handling
| Parameter | Value |
|---|---|
| Dosage studied | 20 mg |
| Minimum order quantity | 1 Kg |
Applications
5 formatsFormats the supplier has run at commercial scale. No inclusion levels have been supplied for this listing yet.
BeveragesFunctional FoodsGummiesPowder BlendsTablets
Guides that cover this
- Application guide
Formulating for cognitive health: mechanisms, doses and constraints
Nootropic is a positioning word, not a mechanism. What the documented materials in this category are actually doing, and the formulation constraints that decide between them.